Pfizer’s Strategic Gambit: A $7.3 Billion Entry into the Weight-Loss Arena
Published on 09/22/2025 at 09:36 | Redaktion boerse-global.deIn a move signaling its serious intent to capture a share of the lucrative anti-obesity drug market, US pharmaceutical titan Pfizer is reportedly nearing a landmark $7.3 billion acquisition of the specialist firm Metsera. This strategic play, as reported by the Financial Times, would position Pfizer as a direct competitor to current industry leaders Eli Lilly and Novo Nordisk in one of the pharmaceutical sector’s most dynamic growth areas.
This potential acquisition arrives at a pivotal moment for Pfizer. The company has been navigating a post-pandemic downturn with declining revenues following the wind-down of its COVID-related business. The urgent search for new growth drivers has made the highly promising anti-obesity medication category a prime target for expansion.
Key Strategic Drivers for Pfizer:
• Establishing... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
